NKGN (nkgenbiotech.com) Koefisien nilai perusahaan marang pendapatan

NKGen Biotech, Inc. (NKGN) is creating a unique allogeneic NK-cell ecosystem to combat Alzheimer's disease, yet the company faces a severe liquidity shortage. The EV/Sales history clearly illustrates the business valuation relative to revenue, with the current metric standing at . The development of cell therapy is supported by joint research with leading medical centers to fight neurodegeneration.
Rincian metrik keuangan lan pasar NKGen (NKGN)

This indicator determines the market value of the business inclusive of net debt, comparing it to annual sales volume to identify asset overvaluation. By analyzing the Enterprise Value to Revenue (EV/Revenue) chart, an investor can see the ratio of total Enterprise Value (EV) to operating income, which is critical for NKGen Biotech, Inc. (NKGN), as its unique developments in cellular neurology create high barriers to entry.